tradingkey.logo

Cardiol Therapeutics Inc <CRDL.TO> expected to post a loss of 11 cents a share - Earnings Preview

ReutersAug 20, 2025 8:05 PM
  • Cardiol Therapeutics Inc CRDL.TO is expected to show no change in quarterly revenue when it reports results on November 12 (estimated) for the period ending September 30 2025

  • ​LSEG's mean analyst estimate for Cardiol Therapeutics Inc is for a loss of 11 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 1.3% in the last three months. ​

  • Wall Street's median 12-month price target for Cardiol Therapeutics Inc is $9.00, about 87.3% above its last closing price of $1.14

Previous quarterly performance (using preferred earnings measure in Canadian dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Jun. 30 2025

-0.12

-0.12

-0.10

Beat

18.9

Mar. 31 2025

-0.13

-0.13

-0.10

Beat

25.9

Dec. 31 2024

-0.10

-0.11

-0.09

Beat

15.6​

Sep. 30 2024

-0.11

-0.11

-0.18

Missed

-58.8

​​Jun. 30 2024

-0.13

-0.13

-0.10

Beat

21.1

Mar. 31 2024

-0.08

-0.10

-0.14

Missed

-33.3​

Dec. 31 2023

-0.12

-0.12

Met

0

Sep. 30 2023

-0.12

-0.12

-0.09

Beat

25

This summary was machine generated August 20 at 20:05 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI